Gantenerumab reduces brain amyloid-β proteoforms: Biochemical evaluation in dominantly inherited Alzheimer disease. (PubMed, medRxiv) - Oct 11, 2026 - "In contrast, solanezumab treatment did not show significant effect on the soluble or insoluble levels of Aβ and tau proteoforms in comparison to samples from non-treated DIAD individuals. Significance: These findings support that ATT with gantenerumab, an antibody that targets fibrillar Aβ, can remove insoluble Aβ from the DIAD brain and also mitigate "downstream" biochemical and pathophysiological changes associated with AD."
Journal • Alzheimer's Disease • CNS Disorders
|
|
; Brian A Gordon; C Dirk Keene; Catherine J Mummery; Celeste M Karch; Charlene Supnet-Bell; Charles White; Chengjie Xiong; Colin L Masters; Daniel Yen; David Aguillón; David B Clifford; Eric McDade; Erik D Roberson; Erin E Franklin; Ghulam Surti; Ging-Yuek Robin Hsiung; Gregory Klein; Guoqiao Wang; Huifangjie Farsad; James J Lah; Jasmeer Chhatwal; Jie Chen; Jinbin Xu; Johannes Levin; John C Morris; John Ringman; John Sims; Jonathan Glass; Jorge Llibre-Guerra; Julia K Kofler; Kazushi Suzuki; Lawrence S Honig; Mario Masellis; Marla Gearing; Martin R Farlow; Mathias Jucker; Matthew P Frosch; Natalie S Ryan; Neelum T Aggarwal; Nick C Fox; Nicolas R Barthélemy; Paolo Vitali; Paul Delmar; Randall J Bateman; Raquel Sánchez-Valle; Reid Coyle; Richard J Perrin; Roger Clarnette; Roy Yaari; Sandra E Black; Sarah B Berman; Serge Guthier; Soumya Mukherjee; Tammie L S Benzinger; Taraneh Atri; Thomas D Bird; Tobias Bittner; Vitaliy Ovod; William S Brooks; Yan Li; Yingxin He
|